

Fabiana Castiglione

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2921589/publications.pdf>

Version: 2024-02-01

173
papers

7,513
citations

57758

44
h-index

58581

82
g-index

174
all docs

174
docs citations

174
times ranked

6916
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 76-84.	1.9	6
2	David Against Goliath: Direct Comparison of Handheld Bowel Sonography and Magnetic Resonance Enterography for Diagnosis of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 563-569.	1.9	3
3	Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e711-e722.	4.4	41
4	P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn's disease patients failure to TNF inhibitors. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i542-i543.	1.3	0
5	P225 David against Goliath: direct comparison of hand-held bowel sonography and magnetic resonance enterography for diagnosis of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i275-i275.	1.3	0
6	Post-operative morbidity in Crohn's disease: what is the impact of patient-, disease- and surgery-related factors?. <i>International Journal of Colorectal Disease</i> , 2022, 37, 411-419.	2.2	5
7	Incident Colorectal Cancer in Inflammatory Bowel Disease. <i>Cancers</i> , 2022, 14, 721.	3.7	5
8	P268 IBD and Covid-19 in Italy: comparisons between first and second pandemic wave. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i307-i308.	1.3	0
9	P384 Postoperative Endoscopic Recurrence In Patients With Crohn's Disease After "Curative" Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i384-i385.	1.3	2
10	P355 Exceeding treatment expectations in Crohn's disease: transmural healing and a new definition of deep remission. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i365-i365.	1.3	0
11	P647 Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i561-i561.	1.3	0
12	Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis. <i>Cells</i> , 2022, 11, 743.	4.1	36
13	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.9	22
14	OC.12.4 EXCEEDING TREATMENT EXPECTATIONS IN CROHN'S DISEASE: TRANSMURAL HEALING AND A NEW DEFINITION OF DEEP REMISSION. <i>Digestive and Liver Disease</i> , 2022, 54, S99.	0.9	0
15	T.06.8 COMPARATIVE OBJECTIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN A REAL-LIFE COHORT OF ACTIVE CROHN'S DISEASE PATIENTS FAILURE TO TNF INHIBITORS. <i>Digestive and Liver Disease</i> , 2022, 54, S140-S141.	0.9	0
16	PC.01.4 REDUCED IMMUNE RESPONSE INDUCED BY TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IG-IBD STUDY. <i>Digestive and Liver Disease</i> , 2022, 54, S64-S65.	0.9	0
17	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	3.7	25
18	Wernicke Encephalopathy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, e70-e71.	1.9	0

#	ARTICLE	IF	CITATIONS
19	The Impact of Intestinal Ultrasound on the Management of Inflammatory Bowel Disease: From Established Facts Toward New Horizons. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	5
20	MR-enterography in Crohn's disease: what MRE mural parameters are associated to one-year therapeutic management outcome?. <i>British Journal of Radiology</i> , 2021, 94, 20200844.	2.2	7
21	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. <i>Digestive and Liver Disease</i> , 2021, 53, 712-716.	0.9	6
22	Ultrasonography-Based Management of Sclerosing Mesenteritis: From Diagnosis to Follow-Up. <i>International Medical Case Reports Journal</i> , 2021, Volume 14, 187-190.	0.8	2
23	Lactose Intolerance Assessed by Analysis of Genetic Polymorphism, Breath Test and Symptoms in Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2021, 13, 1290.	4.1	17
24	P635 Assessment of sarcopenia and nutritional status in a cohort of patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S570-S571.	1.3	0
25	P621 Lactose intolerance assessed by analysis of genetic polymorphism, breath test and symptoms in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S561-S562.	1.3	0
26	Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure. <i>Frontiers in Immunology</i> , 2021, 12, 694217.	4.8	57
27	Chemotherapy-Induced Remission of Steroid-Dependent Ulcerative Colitis Associated With Rectal Hodgkin Lymphoma. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e81-e82.	1.9	1
28	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1432-1441.	3.7	11
29	In Silico Preliminary evaluation of Cx601 as new therapeutic approach in hospital clinical paths. <i>European Journal of Public Health</i> , 2021, 31, .	0.3	0
30	Exclusive Enteral Nutrition in Adult Crohn's Disease: an Overview of Clinical Practice and Perceived Barriers. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 493-501.	2.3	8
31	Crohn's disease and Takayasu's arteritis: are they associated?. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 1472-1484.	0.7	2
32	Assessment of bioelectrical phase angle as a predictor of nutritional status in patients with Crohn's disease: A cross sectional study. <i>Clinical Nutrition</i> , 2020, 39, 1564-1571.	5.0	39
33	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. <i>Digestive and Liver Disease</i> , 2020, 52, 44-50.	0.9	7
34	Impact of intestinal ultrasound on the management of patients with inflammatory bowel disease: how to apply scientific evidence to clinical practice. <i>Digestive and Liver Disease</i> , 2020, 52, 9-18.	0.9	25
35	The VERSIFY Trial: What About Ultrasound Assessment?. <i>Gastroenterology</i> , 2020, 158, 1176-1177.	1.3	0
36	The impact of a dedicated contact centre on the clinical outcome of patients with inflammatory bowel disease during the COVID-19 outbreak. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095958.	3.2	4

#	ARTICLE	IF	CITATIONS
37	Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease: The SuPREMe-CD Study - A Randomized Clinical Trial. <i>Annals of Surgery</i> , 2020, 272, 210-217.	4.2	105
38	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	3.1	11
39	Noninvasive monitoring of inflammatory bowel disease in the post COVID-19 era. <i>Digestive and Liver Disease</i> , 2020, 52, 1236-1237.	0.9	7
40	OC.12.6 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1. <i>Digestive and Liver Disease</i> , 2020, 52, S39-S40.	0.9	0
41	Treatmentâ€based risk stratification of infections in inflammatory bowel disease: A comparison between antiâ€tumor necrosis factorâ€± and nonbiological exposure in realâ€world setting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 36, 1859-1868.	2.8	0
42	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020, 69, 1213-1217.	12.1	283
43	Effectiveness of ustekinumab dose escalation in Crohnâ€™s disease patients with insufficient response to standardâ€dose subcutaneous maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 135-142.	3.7	51
44	P255 Predictors of postoperative morbidity in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S277-S278.	1.3	0
45	Association between Health-Related Quality of Life and Nutritional Status in Adult Patients with Crohnâ€™s Disease. <i>Nutrients</i> , 2020, 12, 746.	4.1	14
46	Preventing recurrence in Crohnâ€™s disease: the Kono-S anastomosis with two-layer technique. <i>Techniques in Coloproctology</i> , 2020, 24, 1213-1214.	1.8	4
47	Evaluation of nutritional adequacy in adult patients with Crohnâ€™s disease: a cross-sectional study. <i>European Journal of Nutrition</i> , 2020, 59, 3647-3658.	3.9	20
48	New Predictive Equations for Estimating Resting Energy Expenditure in Adults With Crohn's Disease. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 1021-1028.	2.6	10
49	Can a transition clinic bridge the gap between paediatric and adult inflammatory bowel disease care models?. <i>Digestive and Liver Disease</i> , 2020, 52, 516-527.	0.9	8
50	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	1.9	51
51	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 144-164K.	1.3	958
52	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 273-284.	1.3	250
53	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Caseâ€Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 450-459.	1.9	33
54	P.07.24 AZATHIOPRINE VS MESALAMINE FOR PREVENTION OF POST-OPERATIVE CLINICAL RELAPSE IN CROHN'S DISEASE PATIENTS WITH SEVERE ENDOSCOPIC RECURRENCE: DATA ON EFFICACY AND SAFETY FROM AN IG-IBD MULTICENTER RANDOMIZED DOUBLE-BLIND DOUBLE-DUMMY TRIAL. <i>Digestive and Liver Disease</i> , 2019, 51, e232.	0.9	0

#	ARTICLE	IF	CITATIONS
55	PT09.5: Evaluation and Prediction and of Resting Energy Expenditure in Adult Crohn Disease. <i>Clinical Nutrition</i> , 2019, 38, S53.	5.0	0
56	Successful outcome of the transitional process of inflammatory bowel disease from pediatric to adult age: A five years experience. <i>Digestive and Liver Disease</i> , 2019, 51, 524-528.	0.9	7
57	Multi-detector CT enterography in active inflammatory bowel disease: Image quality and diagnostic efficacy of a low-radiation high contrast protocol. <i>Clinical Imaging</i> , 2019, 58, 27-33.	1.5	9
58	OC.13.6 AUGMENTED ENDOSCOPY FOR SURVEILLANCE OF COLONIC INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH NETWORK META-ANALYSIS. <i>Digestive and Liver Disease</i> , 2019, 51, e115.	0.9	0
59	Escalating dose of adalimumab as monotherapy to treat unusual giant and refractory oral&pharyngeal ulcerations in Crohn's disease. <i>Dermatologic Therapy</i> , 2019, 32, e12868.	1.7	2
60	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.9	36
61	One&year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1026-1039.	3.7	111
62	P535 Azathioprine vs. mesalamine for prevention of post-operative clinical relapse in Crohn&TM's disease patients with severe endoscopic recurrence: data on efficacy and safety from an IG-IBD multi-centre randomised double-blind double-dummy trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S381-S381.	1.3	0
63	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1805-1812.	1.9	30
64	Late-onset Crohn&TM's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease &AGED&TM study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1361-1369.	1.6	14
65	Nutritional Rehabilitation in Patients with Malnutrition Due to Crohn&TM's Disease. <i>Nutrients</i> , 2019, 11, 2947.	4.1	11
66	Peritoneal inclusion cysts in Crohn&TM's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1070-1072.	1.6	1
67	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	2.6	27
68	Augmented Endoscopy for Surveillance of Colonic Inflammatory Bowel Disease: Systematic Review With Network Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 714-724.	1.3	20
69	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn&TM's Disease. <i>Digestive and Liver Disease</i> , 2019, 51, 640-647.	0.9	14
70	Psoriasis Features in Patients with Inflammatory Bowel Disease. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 1001-1003.	0.2	1
71	Diagnostic Accuracy of Ultrasonography in the Detection of Postsurgical Recurrence in Crohn&TM's Disease: A Systematic Review with Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 977-988.	1.9	52
72	Gut microbiota and Crohn&TM's disease. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2018, 11, 65-72.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Cross-sectional evaluation of transmural healing in Crohn's disease: Mural and mesenteric parameters – Authors' reply. Digestive and Liver Disease, 2018, 50, 211-212.	0.9	3
74	Ustekinumab in the management of Crohn's disease: Expert opinion. Digestive and Liver Disease, 2018, 50, 653-660.	0.9	22
75	Combined Endoscopic/Sonographic-based Risk Matrix Model for Predicting One-year Risk of Surgery: A Prospective Observational Study of a Tertiary Centre Severe/Refractory Crohn's Disease Cohort. Journal of Crohn's and Colitis, 2018, 12, 784-793.	1.3	25
76	Transmural healing in Crohn's disease: Beyond mural findings – Authors' reply. Digestive and Liver Disease, 2018, 50, 104-105.	0.9	4
77	Letter: which risk factors for post-operative recurrence in Crohn's disease can be modified?. Alimentary Pharmacology and Therapeutics, 2018, 48, 1031-1032.	3.7	1
78	Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel Diseases and Celiac Disease. Digestive Diseases, 2018, 36, 271-280.	1.9	32
79	Diagnostic Accuracy of 3-Dimensional Endoanal Ultrasound in Identifying Perianal Crohn's Fistulas. Diseases of the Colon and Rectum, 2018, 61, 931-937.	1.3	12
80	P.02.15 SUPREME-CD STUDY: SURGICAL PREVENTION OF ANASTOMOTIC RECURRENCE BY EXCLUDING MESENTERY IN CROHN'S DISEASE. PRELIMINARY RESULTS AND TRIAL PROTOCOL. Digestive and Liver Disease, 2018, 50, e138.	0.9	1
81	OC.02.5 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART1. Digestive and Liver Disease, 2018, 50, e73.	0.9	0
82	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.9	42
83	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, 604-617.	0.9	47
84	Cross-sectional evaluation of transmural healing in patients with Crohn's disease on maintenance treatment with anti-TNF alpha agents. Digestive and Liver Disease, 2017, 49, 484-489.	0.9	92
85	Bowel Damage in Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 143-151.	1.9	40
86	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. Digestive and Liver Disease, 2017, 49, 1298-1305.	0.9	13
87	Diagnostic efficacy of single-pass abdominal multidetector-row CT: prospective evaluation of a low dose protocol. British Journal of Radiology, 2017, 90, 20160612.	2.2	6
88	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD – AEGED study. Digestive and Liver Disease, 2017, 49, 17-23.	0.9	35
89	Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Frontiers in Pharmacology, 2017, 8, 867.	3.5	8
90	Adherence in ulcerative colitis: an overview. Patient Preference and Adherence, 2017, Volume 11, 297-303.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Kono-type anastomosis in a patient with severe multi-recurrent Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1565-1566.	2.2	12
92	Efficacy of a contact center-based communication in optimizing the care of inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2016, 48, 869-873.	0.9	10
93	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 913-924.	1.3	30
94	Dramatic improvement of severe acne pustulosa after adalimumab in a patient with ulcerative colitis. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 348-350.	0.5	6
95	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.9	34
96	The burden of anaemia in patients with inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2016, 48, 267-270.	0.9	22
97	Dactylitis in enteropathic spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 842-847.	0.8	8
98	Different Profile of Efficacy of Thiopurines in Ulcerative Colitis and Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2570-2575.	1.9	18
99	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1104-1113.	27.0	366
100	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1642-1652.	1.3	27
101	Articular and other Immune-Mediated Extra-Intestinal Manifestations in Inflammatory Bowel Diseases. <i>European Journal of Inflammation</i> , 2014, 12, 251-259.	0.5	1
102	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	1.3	53
103	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.9	39
104	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	5.8	84
105	Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 3516.	3.3	30
106	Fluoroquinolone-based protocols for eradication of <i>Helicobacter pylori</i> . <i>World Journal of Gastroenterology</i> , 2014, 20, 8947-56.	3.3	4
107	Surgery-induced remission of extraintestinal manifestations in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e504-e505.	1.3	6
108	The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 501-512.	3.7	152

#	ARTICLE	IF	CITATIONS
109	Adalimumab in active ulcerative colitis: A "real-life" observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.9	72
110	Hypokalemic myopathy in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 680.	1.3	3
111	Giant lateral spreading tumor in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e710-e711.	1.3	0
112	Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis <sc>B</sc> or <sc>C</sc> virus infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 200-208.	2.0	28
113	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 556-585.	1.3	541
114	Transmural Healing Evaluated by Bowel Sonography in Patients with Crohn's Disease on Maintenance Treatment with Biologics. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	76
115	Noninvasive Diagnosis of Small Bowel Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 991-998.	1.9	116
116	Discovertebral Erosions in Patients with Enteropathic Spondyloarthritis. <i>Journal of Rheumatology</i> , 2012, 39, 2332-2340.	2.0	7
117	Risk factors for inflammatory bowel diseases according to the "hygiene hypothesis": A case-control, multi-centre, prospective study in Southern Italy. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 324-329.	1.3	81
118	Reply to Dr Geary's letter. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 870.	1.3	0
119	Diagnostic accuracy of confocal laser endomicroscopy in diagnosing dysplasia in patients affected by long-standing ulcerative colitis. <i>World Journal of Gastrointestinal Endoscopy</i> , 2012, 4, 414.	1.2	45
120	Randomized Controlled Trials in Active Luminal Crohn's Disease. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 290-296.	0.8	0
121	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	4.4	316
122	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 484-498.	1.3	93
123	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2011, 43, 1-20.	0.9	125
124	Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 724-734.	3.7	146
125	Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 758-766.	1.9	41
126	Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 291-300.	1.3	21

#	ARTICLE	IF	CITATIONS
127	Monster parastomal pyoderma gangrenosum effectively treated by topical tacrolimus. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 218-219.	1.3	6
128	NEWLY DIAGNOSED NEOPLASIA IN A COHORT OF CROHN'S DISEASE PATIENTS TREATED OR UNTREATED WITH INFLIXIMAB FOLLOWED UP IN THE LONG TERM: A MULTICENTER MATCHED-PAIR STUDY. <i>Digestive and Liver Disease</i> , 2009, 41, S127-S128.	0.9	0
129	P241 - Loci at chr21q22 and MHC are associated to UC in Italian population. <i>Journal of Crohn's and Colitis</i> , 2009, 3, S106.	1.3	0
130	Gestational diabetes insipidus: a morphological study of the placenta. <i>Pathologica</i> , 2009, 101, 227-9.	3.4	1
131	Performance of two commercial blood IFN- γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF- α treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008, 27, 907-913.	2.9	95
132	Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1240-1245.	1.9	90
133	Bowel sonography in occlusive Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 269-270.	1.3	0
134	Lack of efficacy of azathioprine in the treatment of axial arthritis complicating Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 357-358.	1.3	0
135	Placental findings in pregnancy-associated haemolytic uremic syndrome: clinicomorphological study of three cases. <i>Pathologica</i> , 2008, 100, 451-3.	3.4	0
136	Bowel sonography in adult celiac disease: diagnostic accuracy and ultrasonographic features. <i>Abdominal Imaging</i> , 2007, 32, 73-77.	2.0	14
137	Lower Prevalence of Diverticulosis in Patients with Ulcerative Colitis. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1164-1168.	1.3	18
138	Increased risk of breast cancer in first-degree relatives of Crohn's disease patientsAn IG-IBD study. <i>Digestive and Liver Disease</i> , 2006, 38, 18-23.	0.9	19
139	Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1117-1125.	3.7	189
140	Bowel sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 486-490.	1.9	60
141	Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 243-249.	4.4	48
142	Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. <i>Gut</i> , 2006, 55, 228-233.	12.1	123
143	The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. <i>European Review for Medical and Pharmacological Sciences</i> , 2006, 10, 17-22.	0.7	81
144	Noninvasive Diagnosis of Small Bowel Crohn's Disease: Combined Use of Bowel Sonography and Tc-99M-Hmpao Leukocyte Scintigraphy. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 376-382.	1.9	45

#	ARTICLE	IF	CITATIONS
145	Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. <i>Digestive and Liver Disease</i> , 2005, 37, 407-417.	0.9	32
146	Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study. <i>Digestive and Liver Disease</i> , 2005, 37, 577-583.	0.9	75
147	Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 387-391.	1.1	87
148	Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. <i>Digestive and Liver Disease</i> , 2004, 36, 121-124.	0.9	31
149	<i>Helicobacter pylori</i> impairs iron absorption in infected individuals. <i>Digestive and Liver Disease</i> , 2004, 36, 455-460.	0.9	85
150	Bowel Wall Thickness at Abdominal Ultrasound and the One-Year-Risk of Surgery in Patients with Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 1977-1983.	0.4	67
151	Capsule endoscopy is safe and effective after small-bowel resection. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 135-138.	1.0	31
152	Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 219-223.	1.6	36
153	Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 517-523.	3.7	82
154	Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 1107-1112.	3.7	90
155	Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial. <i>Current Pharmaceutical Design</i> , 2002, 8, 1013-1019.	1.9	50
156	Crohn disease: susceptibility and disease heterogeneity revealed by HLA genotyping. <i>Human Immunology</i> , 2001, 62, 701-704.	2.4	11
157	Hepatitis B and C Virus Infection in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2001, 7, 287-294.	1.9	91
158	Response to Tursi Letter. <i>Journal of Clinical Gastroenterology</i> , 2001, 32, 274-275.	2.2	0
159	Prognostic value of serum biological markers in patients with hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2001, 7, 3504-9.	7.0	30
160	Accuracy of enteroclysis in Crohn's disease of the small bowel: a retrospective study. <i>European Radiology</i> , 2000, 10, 1894-1898.	4.5	46
161	Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine. <i>American Journal of Gastroenterology</i> , 2000, 95, 2394-2395.	0.4	10
162	Hepatitis related to cytomegalovirus infection in two patients with Crohn's disease treated with azathioprine. <i>Digestive and Liver Disease</i> , 2000, 32, 626-629.	0.9	16

#	ARTICLE	IF	CITATIONS
163	Orocecal Transit Time and Bacterial Overgrowth in Patients with Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 63-66.	2.2	73
164	A Mesalazine Tablet in the Distal Ileum of a Patient With Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2000, 30, 99-100.	2.2	0
165	Primary Systemic Amyloidosis With Giant Hepatomegaly and a Swiftly Progressive Course. <i>Journal of Clinical Gastroenterology</i> , 1997, 24, 173-175.	2.2	17
166	Power Doppler sonography to evaluate response to percutaneous ethanol injection in hepatocellular carcinoma. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1997, 29, 548-53.	0.5	4
167	Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. <i>The Italian Journal of Gastroenterology</i> , 1996, 28, 199-204.	0.1	73
168	Juvenile rheumatoid arthritis, Crohn's disease and Turner's syndrome: a novel association. <i>Clinical and Experimental Rheumatology</i> , 1996, 14, 449-50.	0.8	10
169	Nocturnal oesophageal motor activity is dependent on sleep stage.. <i>Gut</i> , 1993, 34, 1653-1659.	12.1	44
170	Oesophageal pH-Metry: Should Meals Be Standardized?. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 350-354.	1.5	23
171	Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity. <i>Digestive Diseases and Sciences</i> , 1992, 37, 198-204.	2.3	26
172	Reproducibility of Ambulatory Gastric pH Recordings in the Corpus and Antrum: Effect of Food, Time, and Electrode Position. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 1076-1083.	1.5	35
173	Twenty-four-hour pattern of esophageal motility in asymptomatic volunteers. <i>Digestive Diseases and Sciences</i> , 1990, 35, 1190-1197.	2.3	32